Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could replace IV drips for nerve disease patients

NCT ID NCT06637072

Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether adults with CIDP, a nerve disorder causing weakness and numbness, could safely switch from regular intravenous immunoglobulin (IVIg) infusions to a new injectable drug called efgartigimod PH20 SC. Twenty-three participants who were stable on IVIg were given the new drug as a shot under the skin for 12 weeks. The main goal was to see how many could stay on the new treatment without needing to go back to IVIg.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
efgartigimod PH20 SC (a biologic drug given as a shot under the skin)
What this could lead to
If this works, it could offer people with CIDP a more convenient treatment option that requires fewer clinic visits than regular IV infusions.
What could go wrong
This is a small, early-phase study with only 23 participants and no comparison group. Results may not apply to everyone with CIDP, and side effects or lack of effectiveness could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

23 people

The number who actually took part.

Started

Dec 2024

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent * Is diagnosed with CIDP (confirmed or possible CIDP) according to the criteria of the European Academy of Neurology/Peripheral Nerve Society * Is being treated with IVIg every 3-6 weeks, on a stable dose and dosing interval (between 0.5-2 g/kg) for at least 3 doses * If receiving oral corticosteroids, this should be at a stable dose of less than 20 mg a day or less than 40 mg every other day, for at least a month. * If receiving nonsteroidal immunosuppressive medication, this should be at a stable dose for at least 3 months Exclusion Criteria: * Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk * Types of other polyneuropathy other than CIDP

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic inflammatory demyelinating polyneuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic inflammatory demyelinating polyneuropathy

Contacts and locations

Locations

  • Cedar Health Research - Dallas

    Dallas, Texas, 75251, United States

  • Erlanger Neuroscience Institute

    Chattanooga, Tennessee, 37403, United States

  • Horizon Clinical Research: Gill Neuroscience

    Cypress, Texas, 21216, United States

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States

  • National Neuromuscular Research Institute

    Austin, Texas, 78759, United States

  • Neurology Associates PA

    Maitland, Florida, 32751, United States

  • Northwest Houston Neurology - Cypress

    Cypress, Texas, 77429, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • SRI International - ClinEdge

    Plymouth, Michigan, 48170, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

  • Velocity Clinical Research

    Lafayette, Louisiana, 70508, United States

  • Velocity Clinical Research

    Raleigh, North Carolina, 27607, United States

  • Visionary Investigators Network

    Miami, Florida, 33180, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.